A condition may be “rare,” but no person should feel invisible.
At JY MedTech, we recognize the resilience of the rare disease community and the importance of continued collaboration across science and healthcare.
Today, we stand with patients, families, advocates, and researchers working to increase awareness and accelerate progress.
JYMed Receives South Korean K-DMF Registration for Teriparatide Acetate API
JYMed Peptide is pleased to announce that Hubei JXBio Pharmaceutical Co., Ltd, its peptide API manufacturing site, has...




0 Comments